Articles

Here’s the key to retiring together as a couple without fighting about money

Retirement is a team effort, yet fewer than 3 in 5 couples discuss plans with their partners.

Marvell’s stock falls in the wake of these two competitive concerns

There are new fears on Wall Street related to the future of Marvell’s work with Amazon and its potential to capitalize on opportunity with Microsoft.

The maid of honor approved my bridesmaid’s dress, but now wants me to buy a new one. What should I do?

“While I’d like to push back more, I know myself and will end up caving and buying a new dress.”

Investors’ bearishness is often overdone — but their bubble fears may be spot-on

There was widespread concern about dot-com stocks and the housing market before those crashes.

Musk suggests this underrated AI business could be a big driver of SpaceX’s valuation

With SpaceX’s valuation expected to skyrocket, its CEO largely credits satellites, rocket launches — and the company’s plan to solve a major AI-industry problem.

Intel, Adobe and these other ‘AI loser’ stocks could get left behind in the next phase of the tech boom

These 12 tech companies are most vulnerable to having their business models upended by the AI revolution, according to Wedbush Securities.

How Nvidia’s stock can benefit from this emerging trend in AI models

As the industry shifts toward AI models with better memory and understanding, Citi expects a new Nvidia offering to best its competitors.

Why this veteran strategist is dropping his preference for tech stocks after 15 years

More competition is coming for the “juicy profit margins” of the “Magnificent Seven,” Ed Yardeni said, and he’s ready to look elsewhere for gains.

Paramount launches hostile bid for Warner Bros. with $108.4 billion offer, besting Netflix by $25 billion

Paramount Skydance CEO David Ellison is not ready to go down without a fight for Warner Bros. Discovery, making a counter offer that is $18 billion more than that offered by Netflix.

Why I’m moving my money out of U.S. stocks — just like Warren Buffett

You’d have made a lot more this year investing in non-U.S. stock markets. These ETFs are worth considering now.

Structure Therapeutics details positive trial data for a weight-loss pill, and the stock rockets

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron, that just showed positive results from a Phase 2 trial.

Young men aren’t investing in a 401(k) for retirement — they’re banking on bitcoin

Income level, education and political beliefs all influence crypto ownership.
1 22 23 24 25 26 2,495